GVK BIO unveils new brand, aims to be among top 3 Asian firms

City-based contract research company GVK Biosciences (GVK BIO), which unveiled a new brand, today said it aims to be among the top three clinical research organisations in Asia in the next five years.
"GVK BIO is well-known as a discovery services company. Today in our estimate we are No. 4 or No. 5 in the country in clinical research and clinical development. Our goal is to be in top three in Asia in the next five years through the new brand Clinogent," GVK Biosciences Chief Executive Manni Kantipudi said here.
He was speaking to reporters after unveiling the firm's new brand, 'Clinogent', in the clinical development industry to offer integrated clinical trial outsourcing solutions.

"The launch of a new brand (Clinogent) is part of GVK BIO's growth plan in taking the organisation to the next level and creating a benchmark in the industry," he said.
GVK BIO plans to add 50 more beds to its Ahmedabad facility to carry out clinical trials and start an analytical laboratory in the next three months.
"We are looking to expand our capacity...We have space in Ahmedabad facility. We are starting with a bio-analytical laboratory in Ahmedabad and add another 50 beds in Ahmedabad," said Chetan Tamhankar, Senior Vice-President (Clinical Development), GVK BIO.

The new addition of beds will be to the company's existing facilities in Hyderabad and Ahmedabad.

'Clinogent' reflects the company's focus on further strengthening its operational expertise and technology to evolve into a specialist and comprehensive service offering entity in the clinical research and development market, Kantipudi said.
"Clinogent will be a clinical development service provider, which will be able to address the clinical needs of both innovator bio-pharmaceutical and generics companies world-wide," Kantipudi added.